Core Viewpoint - The announcement regarding the restricted stock incentive plan indicates a positive outlook for the company's performance, with a projected net profit growth of 22.60% for 2024 compared to 2023, meeting performance assessment targets [1] Group 1: Stock Performance - As of October 31, 2025, the stock price of Kewei Medical (301087) closed at 43.71 yuan, down 4.35% from the previous trading day [1] - The stock opened at 45.24 yuan, reached a high of 45.37 yuan, and a low of 43.53 yuan, with a trading volume of 1.92 billion yuan and a turnover rate of 2.22% [1] Group 2: Incentive Plan Details - The first vesting period of the restricted stock incentive plan has been achieved, with 301 individuals receiving a total of 1.821 million shares, accounting for 0.87% of the company's total share capital [1] - The shares are sourced from the company's repurchased A-shares, with the listing date for the vested shares being October 31, 2025 [1] - The grant price has been adjusted to 13.10 yuan per share, and the funds raised will be used to supplement working capital [1] Group 3: Performance Assessment - The company achieved a 100% vesting ratio at the company level due to meeting the performance assessment targets [1] - All 308 individual performance assessments were rated A/good or above, resulting in a 100% vesting ratio at the individual level [1] - The number of vesting individuals was adjusted from 308 to 301 due to some individuals leaving or waiving their contributions, with the total vesting shares adjusted from 1.8384 million to 1.821 million [1]
可孚医疗（301087）披露2024年限制性股票激励计划首次授予部分第一个归属期归属结果暨股份上市公告，10月31日股价下跌4.35%